Literature DB >> 8230024

Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

M F van Lieshout-Zuidema1, F C Breedveld.   

Abstract

OBJECTIVE: To determine the effect of withdrawal of antihyperuricemic therapy on the recurrence of tophi and acute arthritis.
METHODS: We performed a retrospective investigation of 21 patients with tophaceous gout who stopped therapy because they had no arthritis for years, and on examination tophi had disappeared.
RESULTS: Nine patients (43%) had a recurrence of tophi after an average period of 39.6 months (range 4-107 months). Seventeen patients (81%) had attacks of acute arthritis, 6 patients within 6 months. During a mean period of drug discontinuation of 37.6 months no increase in serum creatinine or deterioration in joint function was observed.
CONCLUSION: Based on our data we conclude that intermittent usage of antihyperuricemic drugs will, after a variable period, result in the frequent recurrence of acute arthritis and tophi.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230024

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 2.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Why is gout so poorly managed?

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

4.  Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.

Authors:  Virginie Beslon; Perrine Moreau; Annabel Maruani; Hubert Maisonneuve; Bruno Giraudeau; Jean-Pascal Fournier
Journal:  J Gen Intern Med       Date:  2017-12-04       Impact factor: 5.128

Review 5.  Pathophysiology, clinical presentation and treatment of gout.

Authors:  Gim Gee Teng; Raj Nair; Kenneth G Saag
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Management of gout in older adults: barriers to optimal control.

Authors:  Karl T Hoskison; Robert L Wortmann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 8.  Gout--current diagnosis and treatment.

Authors:  Anne-Kathrin Tausche; Tim L Jansen; Hans-Egbert Schröder; Stefan R Bornstein; Martin Aringer; Ulf Müller-Ladner
Journal:  Dtsch Arztebl Int       Date:  2009-08-24       Impact factor: 5.594

9.  Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood.

Authors:  R Miesel; M Zuber; D Sanocka; R Graetz; H Kroeger
Journal:  Inflammation       Date:  1994-12       Impact factor: 4.092

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.